Drug intelligence / Profile preview

Klebsiella pneumoniae bacteriophage

Development stage
Unknown
Administration
Inhalation, Intravesical, Intravenous, Oral, Topical
01

Overview

Klebsiella pneumoniae bacteriophage refers to a class of lytic viruses (bacteriophages) that specifically target and infect the Gram-negative bacterium *Klebsiella pneumoniae*. These phages bind to specific bacterial surface receptors, such as the capsular polysaccharide (CPS) or lipopolysaccharide (LPS), inject their genetic material, and replicate within the host cell, ultimately causing bacterial lysis and death. This targeted approach is being developed as an alternative or adjunct to traditional antibiotic therapy, particularly for combating multidrug-resistant (MDR) and carbapenem-resistant *K. pneumoniae* (CR-Kp) infections. Various academic institutions and biotechnology companies are investigating single phages or multi-phage cocktails for indications such as ventilator-associated pneumonia (VAP), urinary tract infections (UTIs), and prosthetic joint infections.

Other names
Klebsiella bacteriophageKlebsiella phageanti-Klebsiella pneumoniae bacteriophageanti-Klebsiella pneumoniae phage
02

Targets

K1 CPS (Klebsiella pneumoniae capsular polysaccharide serotype K1)LPS (Lipopolysaccharide)

Beyond the preview

Go deeper on Klebsiella pneumoniae bacteriophage.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Klebsiella pneumoniae bacteriophage.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call